INmune Bio Competitors

INmune Bio (NASDAQ:INMB) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Earnings & Valuation

This table compares INmune Bio and Aligos Therapeutics' top-line revenue, earnings per share and valuation.

Insider & Institutional Ownership

7.4% of INmune Bio shares are owned by institutional investors. 58.9% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares INmune Bio and Aligos Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for INmune Bio and Aligos Therapeutics, as reported by MarketBeat.

INmune Bio currently has a consensus target price of $19.25, suggesting a potential upside of 25.24%. Aligos Therapeutics has a consensus target price of $30.50, suggesting a potential upside of 41.60%. Given Aligos Therapeutics' higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than INmune Bio.

Summary

Aligos Therapeutics beats INmune Bio on 3 of the 5 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Volatility and Risk

Cellectis has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 3.01, meaning that its stock price is 201% more volatile than the S&P 500.

Earnings and Valuation

This table compares Cellectis and INmune Bio's revenue, earnings per share (EPS) and valuation.

INmune Bio has lower revenue, but higher earnings than Cellectis. INmune Bio is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Cellectis and INmune Bio, as provided by MarketBeat.

Cellectis currently has a consensus price target of $24.25, indicating a potential upside of 25.58%. INmune Bio has a consensus price target of $19.25, indicating a potential upside of 25.24%. Given Cellectis' higher possible upside, analysts plainly believe Cellectis is more favorable than INmune Bio.

Insider & Institutional Ownership

33.3% of Cellectis shares are held by institutional investors. Comparatively, 7.4% of INmune Bio shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 58.9% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Cellectis and INmune Bio's net margins, return on equity and return on assets.

Summary

INmune Bio beats Cellectis on 7 of the 13 factors compared between the two stocks.

INmune Bio (NASDAQ:INMB) and TCR2 Therapeutics (NASDAQ:TCRR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

INmune Bio has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500. Comparatively, TCR2 Therapeutics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500.

Institutional & Insider Ownership

7.4% of INmune Bio shares are held by institutional investors. Comparatively, 82.1% of TCR2 Therapeutics shares are held by institutional investors. 58.9% of INmune Bio shares are held by company insiders. Comparatively, 28.0% of TCR2 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for INmune Bio and TCR2 Therapeutics, as provided by MarketBeat.com.

INmune Bio currently has a consensus price target of $19.25, indicating a potential upside of 25.24%. TCR2 Therapeutics has a consensus price target of $39.2857, indicating a potential upside of 63.28%. Given TCR2 Therapeutics' higher possible upside, analysts clearly believe TCR2 Therapeutics is more favorable than INmune Bio.

Valuation and Earnings

This table compares INmune Bio and TCR2 Therapeutics' gross revenue, earnings per share and valuation.

INmune Bio is trading at a lower price-to-earnings ratio than TCR2 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares INmune Bio and TCR2 Therapeutics' net margins, return on equity and return on assets.

Summary

TCR2 Therapeutics beats INmune Bio on 6 of the 10 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Sutro Biopharma and INmune Bio, as reported by MarketBeat.com.

Sutro Biopharma currently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. INmune Bio has a consensus target price of $19.25, indicating a potential upside of 25.24%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts clearly believe INmune Bio is more favorable than Sutro Biopharma.

Profitability

This table compares Sutro Biopharma and INmune Bio's net margins, return on equity and return on assets.

Volatility & Risk

Sutro Biopharma has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sutro Biopharma and INmune Bio's top-line revenue, earnings per share and valuation.

INmune Bio has lower revenue, but higher earnings than Sutro Biopharma. INmune Bio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

78.8% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 7.4% of INmune Bio shares are owned by institutional investors. 28.9% of Sutro Biopharma shares are owned by company insiders. Comparatively, 58.9% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

INmune Bio beats Sutro Biopharma on 8 of the 13 factors compared between the two stocks.

INmune Bio (NASDAQ:INMB) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares INmune Bio and Adaptimmune Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and recommmendations for INmune Bio and Adaptimmune Therapeutics, as reported by MarketBeat.

INmune Bio currently has a consensus target price of $19.25, suggesting a potential upside of 25.24%. Adaptimmune Therapeutics has a consensus target price of $15.50, suggesting a potential upside of 209.38%. Given Adaptimmune Therapeutics' higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than INmune Bio.

Valuation and Earnings

This table compares INmune Bio and Adaptimmune Therapeutics' revenue, earnings per share and valuation.

INmune Bio has higher earnings, but lower revenue than Adaptimmune Therapeutics. INmune Bio is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.4% of INmune Bio shares are held by institutional investors. Comparatively, 99.8% of Adaptimmune Therapeutics shares are held by institutional investors. 58.9% of INmune Bio shares are held by company insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

INmune Bio has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Summary

INmune Bio beats Adaptimmune Therapeutics on 8 of the 13 factors compared between the two stocks.

Vaxart (NASDAQ:VXRT) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vaxart and INmune Bio, as provided by MarketBeat.com.

Vaxart currently has a consensus price target of $15.00, suggesting a potential upside of 153.38%. INmune Bio has a consensus price target of $19.25, suggesting a potential upside of 25.24%. Given Vaxart's higher possible upside, equities analysts plainly believe Vaxart is more favorable than INmune Bio.

Insider & Institutional Ownership

17.9% of Vaxart shares are held by institutional investors. Comparatively, 7.4% of INmune Bio shares are held by institutional investors. 7.3% of Vaxart shares are held by company insiders. Comparatively, 58.9% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Vaxart and INmune Bio's net margins, return on equity and return on assets.

Volatility and Risk

Vaxart has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vaxart and INmune Bio's revenue, earnings per share and valuation.

INmune Bio has lower revenue, but higher earnings than Vaxart. INmune Bio is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Summary

INmune Bio beats Vaxart on 8 of the 12 factors compared between the two stocks.